Abstract: The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This invention is also directed to a human non-immune phage display library. One clone that specifically binds the Cn2 toxin was affinity matured by directed evolution. Three cycles of maturation were performed and several scFv clones were isolated which specifically recognize toxin Cn2 with increased Kd of 446 fold. All variants were monomeric and only variants 6009F, 6105F and 6103E showed to be capable of neutralizing toxin Cn2 and the whole venom. Variant 6009F recognizes a different epitope than that of BCF2, a murine monoclonal antibody raised against scorpion toxin Cn2 which is also capable of neutralizing both Cn2 toxin and the whole venom when tested in mice, as well as that of commercially available polyclonal antibody fragments antivenom from horse.

Abstract: Copper amino acidate diimine nitrate compounds of the formula [Cu(N--N)(N--O)].sup.+NO.sub.3.sup.-, where (N--N) is a diimine selected from 1,10-phenanthroline or 4,7-dimethyl 1,10-phenanthroline and (N--O) is tyrosine-alaninate, threoninate, tryptophanate, valinate, isoleucinate, cysteinate, diglycinate, phenylalaninate, glycinate, histidinate, serinate, tryosinate, aspartate or alaninate and a process for preparing the compounds in which, while maintaining a pH between 5 and 7, a first aqueous solution of Cu(NO.sub.3).sub.2.5H.sub.2 O, having 30 to 35% by weight of elemental copper, is reacted with a second aqueous solution of the diimine having a ratio of 50 to 55% by weight diimine to solution to form a monodiimine nitrate as an intermediate reaction product having the formula [Cu(N--N)(H.sub.2 O).sub.2 ].sup.+ NO.sub.3.sup.

Abstract: This invention refers to a process to obtain new mixed copper aminoacidates complexes from phenanthrolines of an aromatic type to be used as anticancerigenic agents preferably with a therapeutic use for the treatment of liquid and solid cancerigenic tumors such as leukemia. The complexes obtained are of the [Cu (N-N) (N-O)].+-. NO.sub.3 type in which the N-N ligand corresponds to 4, 7 - diphenyl-1, 10 phenanthroline and the N-O ligand preferably corresponds to one of the aminoacidates such as glycinate, alaninate, isoleucinate, leucinate, serinate and valinate. The process is characterized because it includes the following steps: making an aqueous solution based on an aliphatic alcohol and 4, 7 - diphenyl - 1, 10 phenanthroline react with a copper complex preferably Cu NO.sub.3 5H.sub.2 O at room temperature, and immediately after making the obtained product react in an aqueous aminoacidate solution adjusting a slightly alkaline pH.